Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary ...

Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Exelixis today. The company’s shares closed yesterday at $44.39. Take advantage of TipRanks Premium at 50% off! Unlock ...

United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q2 earnings results on Wednesday, July 30th, before market open.The consensus EPS estimate ...

Vericel Corporation (VCEL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago. These figures ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 30, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ...